GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

>for another company to go after that market<
would require substantial clinical and regulatory expense,
which underscores your point (not to mention the time
required to catch up to where we are already)

hard to reconcile that scenario with the suggestion than AT is a
modest/dubious market opportunity compared to FVIII & FIX